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The T cell receptor CTL-associated antigen 4 
(CTLA-4) is recognized as a critical inhibitory 
regulator of the early stages of T cell expansion, 
opposing the actions of CD28-mediated costim-
ulation. Genetic disruption of CTLA-4 expres-
sion results in a polyclonal CD4-dominated 
lymphoproliferative syndrome, which is charac-
terized by T cell infiltration of multiple organs 
and early lethality within 3–4 wk after birth   
(Waterhouse et al., 1995). This pathology is 
dependent on interactions of CD28 with its   
ligands B7-1 and B7-2, as indicated by the lack 
of disease in CTLA-4/B7-1/B7-2 triple KO 
(TKO) mice and the protection afforded by   
repeated  administration  of  CTLA-4  Ig  in 
CTLA-4 KO mice (Mandelbrot et al., 1999).
Based on the recognition of the importance 
of CTLA-4 in the regulation of immune re-
sponses, blocking antibodies against both mouse 
and human forms have been investigated for 
their potential to boost immunological responses 
against  cancer.  Data  from  preclinical  models 
support a significant role for CTLA-4 blockade 
in the induction of durable antitumor immu-
nity (Leach et al., 1996; Shrikant et al., 1999; 
van Elsas et al., 1999; Quezada et al., 2006). 
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Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of 
immune responses. Uniquely among known inhibitory receptors, its genetic ablation results 
in a fulminating and fatal lymphoproliferative disorder. This central regulatory role led to 
the development of antibodies designed to block CTLA-4 activity in vivo, aiming to enhance 
immune responses against cancer. Despite their preclinical efficacy and promising clinical 
activity against late stage metastatic melanoma, the critical cellular targets for their 
activity remains unclear. In particular, debate has focused on whether the effector T cell 
(Teff) or regulatory T cell (T reg cell) compartment is the primary target of antibody-medi-
ated blockade. We developed a mouse expressing human instead of mouse CTLA-4, allowing 
us to evaluate the independent contributions of CTLA-4 blockade of each T cell compart-
ment during cancer immunotherapy in an in vivo model of mouse melanoma. The data show 
that although blockade on effector cells significantly improves tumor protection, unicom-
partmental blockade on regulatory cells completely fails to enhance antitumor responses. 
However, concomitant blockade of both compartments leads to a synergistic effect and 
maximal antitumor activity. We conclude that the combination of direct enhancement of 
Teff cell function and concomitant inhibition of T reg cell activity through blockade of 
CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–
CTLA-4 antibodies during cancer immunotherapy.
© 2009 Peggs et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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question of which are the relevant cellular targets for their an-
titumor activity. To date, effector T cells (Teff) have been 
thought to be the most relevant target for therapeutic activity, 
but the data from the CKO experiments suggest otherwise by 
highlighting the critical role that CTLA-4 plays in T reg cell 
function. The answer is important for the rational develop-
ment  of  combinatorial  immunotherapeutic  strategies.  The 
lack of functional CTLA-4–expressing T reg cell at tumor en-
graftment in the CKO studies proved sufficient to prevent 
sustained tumor growth in 60% of mice (Wing et al., 2008). 
Both we and others, however, have demonstrated that tar-
geted depletion of T reg cells (either with anti-CD25 mAbs or 
in Foxp3-DTR transgenic mice) can be effective as a prophy-
laxis but not as a treatment once tumor engraftment is estab-
lished, a setting which better reflects their clinical usage 
(Onizuka et al., 1999; Quezada et al., 2008). In addition, it is 
possible that quantitative or qualitative differences may exist 
between CTLA-4 ablation and antibody blockade. Thus, the 
relative importance of antibody-mediated blockade of CTLA-4 
in trans on the regulatory compartment as compared with 
blockade in cis on the nonregulatory compartment in tumor 
models and clinical applications remains unclear.
In this study, we used mice expressing human instead of 
mouse CTLA-4 to allow assessment of the influence of uni- 
and bicompartmental blockade on T reg and non–T reg cell 
compartments during in vitro assays and in an in vivo tumor 
model of B16/BL6 melanoma. We show that unicompart-
mental antibody-mediated blockade of CTLA-4 on T reg 
cells modestly reduced suppressive capacity during in vitro 
suppressor assays. This effect was exaggerated by use of 
CTLA4/ T reg cells derived from stable bone marrow chi-
meras, from which T reg cells could be isolated without sig-
nificant contamination by activated effectors. Intriguingly, 
unicompartmental antibody-mediated blockade of CTLA-4 
on T reg cells combined with a GM-CSF–secreting cellular 
vaccine  (Gvax)  had  no  impact  on  tumor  growth  kinetics 
when given after engraftment. Blockade of the non–T reg 
cell compartment in combination with Gvax resulted in de-
layed  tumor  growth  and  rejection  in  12/30  (40%)  mice, 
whereas blockade of both T reg and non–T reg cell popula-
tions resulted in rejection in 22/30 (73%; P = 0.0017). Our 
data are the first to demonstrate the critical importance of 
synergy between the independent contributions of CTLA-4 
blockade in cis and in trans to antitumor activity, illustrating 
that both Teff and T reg cells are relevant targets for the thera-
peutic efficacy of anti–CTLA-4 antibodies.
RESULTS AnD DISCUSSIon
A transgenic mouse model for unicompartmental  
CTLA-4 blockade
Much of the difficulty complicating the interpretation of pre-
vious studies attempting to define the cellular target of CTLA-4 
antibody in blocking experiments has been the presence of 
CTLA-4 on both activated effector and regulatory compart-
ments. Thus, blockade has potentially affected both popula-
tions and assigning relative contributions to experimental 
Furthermore, clinical trials with human anti–human CTLA-4 
(aHuCTLA-4)  mAbs  show  promising  early  results  in  the 
treatment  of  late-stage  metastatic  melanoma  (Hodi  et  al., 
2003; Phan et al., 2003; Ribas et al., 2005; Peggs et al., 2008). 
Despite growing experience of their use in the treatment of 
human cancers, the precise mechanisms underpinning CTLA-
4–mediated control of the immune response and, more spe-
cifically, the antitumor activity of anti–CTLA-4 antibodies, 
remain elusive. Two independent, but not mutually exclu-
sive, hypotheses invoke cell autonomous and non–cell au-
tonomous mechanisms.
A cell autonomous mechanism of action for CTLA-4, 
with CTLA-4 acting when expressed in cis of CD28, is sup-
ported by several lines of data. Studies of both in vitro and in 
vivo systems show higher proliferative capacity of CTLA-4–
deficient CD4+ and CD8+ T cells when compared with their 
WT counterparts (Chambers et al., 1998, 1999; Greenwald 
et al., 2001, 2002). Several mechanisms have been proposed to 
explain such cell autonomous inhibition, including CTLA-4 
outcompeting CD28 for binding to its ligands B7-1 and B7-2 
(for review see van der Merwe and Davis, 2003), as well   
as direct inhibitory signaling through the CTLA-4 cytoplas-
mic tail (Carreno et al., 2000). In contrast, it has remained 
more contentious whether CTLA-4 expressed in trans by 
CD4+CD25+Foxp3+ regulatory T cells (T reg cells) has a di-
rect role in their suppressive function. Constitutive expres-
sion of CTLA-4 is a cardinal feature of T reg cells, although 
the majority of CTLA-4 is found intracellularly in both T reg 
and conventional T cells, even after activation. Two major 
findings have supported a non–cell autonomous inhibitory 
function of CTLA-4. The first is the dominant protection 
against  lethal  lymphoproliferation  afforded  by  WT  mixed 
chimerism  in  the  bone  marrow  transplant  model  using 
CTLA-4/ and WT donors (Bachmann et al., 1999). The 
second is the ability of CTLA-4 blockade to abrogate the 
protective  effect  mediated  by  CD4+CD25+  T  cells  in  an 
adoptive transfer model of colitis (where CD4+CD45RBhigh 
T cell transfer into immunodeficient mice normally results in 
severe colitis; Read et al., 2000, 2006). However, interpreta-
tion of the impact of anti–CTLA-4 on T reg cells is con-
founded by the direct effects that CTLA-4 blockade has on 
non–T reg cells within the same systems, whereas isolation of 
Foxp3-expressing CD4+ T cells from CTLA-4/ animals 
requires immunological manipulations that may have influ-
enced T reg cell development (e.g., the use of TKO mice; 
Read et al., 2006). Nonetheless, the recent demonstration 
that T reg cell–specific CTLA-4 deficiency in conditional 
KO (CKO) mice is associated with a profound reduction in 
their suppressive capacity has definitively proven a role for 
CTLA-4 in T reg cell–mediated suppression (Wing et al., 
2008). CKO mice developed a lethal autoimmune lympho-
proliferative  syndrome  with  a  slightly  slower  tempo  than 
CTLA-4/ mice, illustrating the essential role that CTLA-4 
plays in T reg cell function.
These recent findings have direct relevance for the clinical 
development of anti–CTLA-4 antibodies. They highlight the JEM VOL. 206, August 3, 2009  1719
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showed that only 1/11 aged mice (11–12 mo old) had posi-
tive titers for ANA, compared with 0/8 in a control group of 
WT B6 mice (unpublished data). The incidence of ANA in 
B6 mice has been reported at 20% by 10 mo of age (Chen, 
et al., 2000), suggesting that the rates in HuTg mice are no 
higher. These data suggest a normal development of the my-
eloid and lymphoid compartments in these mice and indicate 
that human CTLA-4 can functionally interact with mouse 
B7 molecules to prevent the lymphoproliferative disease evi-
dent in CTLA-4/ mice.
To further evaluate the regulation of CTLA-4 in HuTg 
mice, we performed in vitro analyses of CTLA-4 expression, 
comparing the temporal profiles of up-regulation in WT and 
HuTg mice after stimulation with anti-CD3 (Fig. S2). The ex-
pression patterns of both cell surface and intracellular CTLA-4 
were very similar over 72 h when comparing WT and HuTg 
mice in either CD8+, CD4+FoxP3+, or CD4+FoxP3 com-
partments, suggesting comparable regulation in the WT and 
HuTg mice. Finally, we performed tumor challenge experi-
ments in the HuTg mice with either the MC38 colonic carci-
noma cell line or the B16 melanoma cell line (both syngeneic), 
treating with anti–CTLA-4 monotherapy (100 µg aHuCTLA-
4, clone 147, on days 3, 6, and 9) or combined anti–CTLA-4 
and an irradiated GM-CSF–secreting B16/BL6 cellular vaccine 
(Gvax; 106 cells on days 3, 6, and 9), respectively. Tumors were 
rejected with a similar kinetic to that previously demonstrated 
in WT mice treated with an anti–mouse CTLA-4 (aMuCTLA-4) 
mAb, suggesting that HuCTLA-4 plays a comparable role in 
vivo in these tumor model systems to that of MuCTLA-4 in 
WT mice (unpublished data).
Unicompartmental CTLA-4 blockade during in vitro 
suppressor assays results in a modest decrease  
in suppressive activity
In accordance with the species-specific binding of anti–CTLA-
4 mAb (Fig. 1, a and b), functional blockade with an aMuCTLA-
4 (clone 9H10) was also species specific (Fig. 2, a and b). 
Purified populations of either CD4+CD25 or CD4+CD25+ 
WT T cells proliferated to a significantly greater degree in the 
presence of aMuCTLA-4 than control IgG in thymidine in-
corporation assays (Fig. 2 a), whereas neither population of pu-
rified cells from HuTg mice showed enhanced proliferation in 
the presence of aMuCTLA-4 (Fig. 2 b). The direct effect on 
purified effector and regulatory WT cells highlights the cell au-
tonomous role of CTLA-4 in inhibiting T cell proliferation. 
The  demonstration  that  aMuCTLA-4  produces  functional 
blockade in a species-specific manner allowed us to examine 
the effects of unicompartmental blockade of either the T reg or 
non–T reg cell populations.
Conventional suppressor assays were performed using 
mixtures of cells purified from WT and HuTg cells (Fig. 2, 
c–e). Blockade on WT CD4+CD25 T cells in the presence 
of HuTg T reg cells resulted in increased baseline prolifera-
tion, but titration of HuTg T reg cells resulted in equivalent 
suppression to that seen without aMuCTLA-4 at ratios of 1:1 
(Fig. 2 c). By comparison, blockade on WT T reg cells did 
endpoints has been impossible. To allow evaluation of uni-
compartmental CTLA-4 blockade, we have taken advantage 
of the fact that human CTLA-4 is capable of interacting with 
mouse B7-1 and B7-2 and generated mice expressing a chi-
meric CTLA-4 molecule composed of the human extracellu-
lar domain and the mouse transmembrane and cytoplasmic 
domains instead of full length mouse CTLA-4.
Both human and mouse CTLA-4 genes are composed of 
four exons, with overall sequence homology of correspond-
ing proteins of 76% (67% in the extracellular [exon 2], 83% 
in the transmembrane [exon 3], and 100% in the intracyto-
plasmic [exon 4] domains). The gene product of exon 1 is a 
signal peptide not expressed in the mature protein. We cre-
ated a chimeric 17-kb DNA construct containing putative 
upstream regulatory sequences required for CTLA-4 expres-
sion and in which the extracellular (exon 2) coding domain 
of mouse CTLA-4 was replaced with that of human CTLA-4. 
This allowed the generation of a human CTLA-4 transgenic 
(HuTg) mouse, which was then backcrossed into the CTLA-
4/ background (Fig. S1). This HuTg mouse permitted re-
constitution of both in vitro and in vivo experimental systems 
in which the composition of T reg and non–T reg cell com-
partments (WT vs. HuTg) could be controlled. The species-
specific  binding  of  anti–CTLA-4  antibodies  then  allowed 
evaluation of unicompartmental CTLA-4 blockade. Intracel-
lular staining for Foxp3 and mouse CTLA-4 confirmed the 
absence of expression of mouse CTLA-4 in HuTg T cells 
(Fig. 1 a). Anti–HuCTLA-4 revealed similar expression   
profiles  of  human  CTLA-4  in  HuTg  CD4+Foxp3  and 
CD4+Foxp3+ populations (Fig. 1 b), as demonstrated for mouse 
CTLA-4 in WT mice (Fig. 1 a).
Homozygous HuTg mice were rescued from the lym-
phoproliferative phenotype of CTLA-4/ mice, suggesting 
normal complementation of CTLA-4 expression in this 
model. These mice had a normal lifespan with no evidence of 
autoimmune disease over a period of followup of >12 mo. 
Similarly to a previously published human CTLA-4 knockin 
mouse (in which both mouse exon 2 and exon 3 were re-
placed with their human homologues [Lute et al., 2005]), 
there was no enlargement of lymphoid organs and no sig-
nificant increase in absolute numbers of total T cells har-
vested from either LNs (Fig. 1 c) or spleens (not depicted). 
There was a small but significant increase in the number of 
CD4+Foxp3+ T cells in HuTg compared with WT mice, 
which could be explained by the increased levels of Ki67 in 
the HuTg CD4+ population (Fig. 1 d). This small increase in 
the number of CD4+Foxp3+ T cells had no impact on the 
overall phenotype of other T cells because the extent of acti-
vation in vivo in HuTg mice, as assessed by flow cytometry 
for surface CD44 and CD62L expression, was essentially in-
distinguishable from that in WT T cells (unpublished data). 
There were no differences between HuTg and WT mice in 
LNs (Fig. 1 e) or spleens (not depicted) in terms of numbers 
of B, dendritic, or NK cells. Furthermore, there was no evi-
dence of increased levels of autoantibodies with age as as-
sessed by antinuclear antibody (ANA) production. ELISAs 1720 ANTI–CTLA-4 TARGETS EFFECTOR AND REGULATORY T CELLS | Peggs et al.
reg cell compartment was increased and titration of WT T 
reg cells resulted in a lesser degree of suppression, which failed 
to approach complete suppression at ratios of 1:1 (Fig. 2 e). 
These data suggest that antibody-mediated CTLA-4 block-
ade influences T cell proliferation by both cell autonomous 
and non–cell autonomous mechanisms, but with a more sub-
tle effect on T reg cells.
Different antibodies may display subtle or more obvious 
differences in terms of mode of action or magnitude of effect. 
To confirm that these findings were specific neither to one 
antibody clone nor to blockade of WT CTLA-4, we per-
formed parallel experiments using alternate anti–CTLA-4 an-
tibodies. Results were comparable using the 9D9 aMu-CTLA-4 
clone (not depicted) and the aHuCTLA-4 clone 147 (Fig. S3). 
not  increase  baseline  proliferation  HuTg  CD4+CD25  T 
cells (Fig. 2 d). Titration of increasing numbers of WT T reg 
cells largely suppressed proliferation but reproducibly failed 
to induce equivalent suppression of thymidine incorporation 
to that seen without aMuCTLA-4 (Fig. 2 d). These results 
could be explained by a slight reduction in the suppressive 
capacity of WT T reg cells after CTLA-4 blockade but do 
not exclude the possibility that the excess thymidine incor-
poration occurred within the WT T reg cell compartment   
in the presence of CTLA-4 blockade and that full suppression 
of CD4+CD25 T cells was achieved. Bicompartmental 
blockade in experiments where both CD4+CD25 and 
CD4+CD25+ T cells were WT showed a possible additive 
effect of blockade. The baseline proliferation of the non–T 
Figure 1.  Functional replacement of mouse CTLA-4 with the human CTLA-4 gene in vivo. (a and b) Flow cytometric analysis of intracellular 
Foxp3 and CTLA-4 in freshly isolated LN CD4+ T cells from WT and HuTg mice, labeled with aMUCTLA-4 (a) and aHuCTLA-4 (b). (c) Absolute CD4+Foxp3+, 
CD4+Foxp3, and CD8+ T cell counts from age-matched WT (empty circles) and HuTg mice (filled circles; 8–10-mo-old mice; n = 8–9 per group). (d) Fre-
quency of Ki67-expressing CD4+Foxp3+, CD4+Foxp3, and CD8+ T cells in LN of WT (empty circles) and HuTg mice (filled circles). (e) Absolute cell counts 
for B cell, NK cell, and dendritic cell populations in LN of WT (empty circles) and HuTg mice (filled circles). Data represent three independent experiments. 
Horizontal bars in c–e represent mean values.JEM VOL. 206, August 3, 2009  1721
BRIEF DEFINITIVE REPORT
effects, whereas this might not occur if alternate pathways 
were responsible for suppression. The selection of T reg cells 
based on CD25 expression from CTLA4/ mice without 
significant contamination by activated Teff has proven diffi-
cult. Generation of CTLA-4/B7-1/B7-2 TKO mice allows 
isolation of T reg cells from a nonactivated background, but 
interpretation of subsequent experiments is potentially com-
plicated both by the lack of B7 molecules on antigen-present-
ing cells during T cell development and on T cells themselves. 
The impact of the latter is particularly hard to predict. B7 
molecules have been demonstrated to mediate reverse signal-
ing into the cell on which they are expressed (Fallarino et al., 
2003; Bodor et al., 2007). Furthermore, PD-L1 has recently 
Thus, the different antibodies seem largely equivalent in terms 
of in vitro suppressor assays.
Inhibitory effects of CTLA-4 during in vitro suppressor 
assays are exaggerated in CTLA-4 Ko T cells
We reasoned that the apparently modest impact of blockade 
of CTLA-4 on the T reg cell compartment might reflect in-
complete functional blockade, the presence and function of a 
ligand-independent form of CTLA-4 (Vijayakrishnan et al., 
2004), or, alternatively, might indicate that suppression in 
this assay is dependent on alternate pathways. These explana-
tions are not mutually exclusive. If the former were true ge-
netic ablation of CTLA-4 might be associated with heightened 
Figure 2.  Unicompartmental blockade with aMuCTLA-4 during in vitro suppressor assays suggests both cell autonomous and non–cell au-
tonomous activities of CTLA-4. Suppressor assays were performed using mixtures of WT and HuTg cells. (a and b) Proliferation of 50,000 purified WT or 
HuTg CD4+CD25 and CD4+CD25+ T cells in response to T cell–depleted splenocytes and anti-CD3 and in the presence of control IgG or aMuCTLA-4, con-
firming the species specificity of the CTLA-4 blockade. (c) Unicompartmental blockade of 50,000 WT CD4+CD25 T cells with aMuCTLA-4, compared with 
control IgG during in vitro suppression by addition of increasing numbers of HuTg CD4+CD25+ T reg cells. (d) Unicompartmental blockade of WT 
CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppression of 50,000 HuTg CD4+CD25 T cells. (e) Bicompartmental 
blockade of both WT CD4+CD25 Teff and CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppressor assays. Data in  
a–e represent three or more independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.1722 ANTI–CTLA-4 TARGETS EFFECTOR AND REGULATORY T CELLS | Peggs et al.
(Fig. 3 a). Furthermore, the flow cytometry profiles of the 
CTLA-4/ T cells (Fig. S4) and relatively modest increase in 
absolute levels of thymidine incorporation (Fig. 3 a) argue 
against a significant contamination of CTLA-4/ T reg cells 
with CTLA-4/ CD4+CD25 T cells. Suppression of CTLA-
4/ CD4+CD25 T cells by CTLA-4/ T reg cells was vir-
tually nonexistent in contrast to the full suppression mediated 
by WT T reg cells (Fig. 3 d). These data confirm that CTLA-4 
has a role in both cell autonomous and non–cell autonomous 
(i.e., T reg cell–mediated) inhibitory regulation of non–T reg 
cells and also a cell autonomous role within the T reg cell 
compartment. These data are entirely consistent with those us-
ing CKO CTLA-4–deficient T reg cells (Wing et al., 2008).
CTLA-4 blockade on both Teff and T reg cell compartments 
is required for maximal antitumor activity
Our data indicate that CTLA-4 expression is important for the 
suppressive capacity of T reg cells. However, the impact of 
antibody-mediated CTLA-4 blockade of the T reg cell com-
partment was relatively modest in the in vitro suppressor assays 
(Fig. 2 d). Furthermore, our previous work had shown that 
depletion of T reg cells after tumor engraftment effected very 
different outcomes from those seen with prophylactic deple-
tion before tumor challenge (Quezada et al., 2008). The lack 
of impact of T reg cell depletion on tumor growth as an iso-
lated therapeutic strategy combined with the modest impact in 
vitro led us to question which cellular targets were important 
for the therapeutic antitumor activity of blocking antibodies in 
vivo. To address this question, we reconstituted immunodefi-
cient RAG2/ mice with cells from WT and HuTg donors 
(Fig. S5). After pan–T cell selection of cells derived from LN 
and spleen, purified populations of CD4+CD25+ T cells were 
mixed with the combined CD4+CD25 and CD8+ fractions 
(henceforth referred to as Teff) in four combinations to allow 
been revealed to be a specific binding partner of B7-1 with an 
affinity intermediate between that for CTLA-4 and B7-1 and 
CD28 and B7-1, with evidence that PD-L1 and B7-1 can 
mediate bidirectional inhibitory signaling (Butte et al., 2007). 
We therefore sought to isolate CTLA-4–deficient T reg cells 
from an alternate source. Because mixed bone marrow chi-
meras  generated  from  CD45.2+CTLA-4/  and  CD45.1+ 
WT donors have been shown to be protected from lympho-
proliferation and capable of apparently normal responses to 
challenge with several pathogens (Bachmann et al., 1999, 2001), 
we purified CTLA-4/ T reg cells from stable chimeras   
using the CD45.1 congenic marker to deplete WT (SJL) 
cells (Fig. S4). Mice were bled 10–12 wk after transplantation 
and only those displaying 40–60% SJL chimerism were used 
for subsequent experiments. The profile of CD25 staining on 
the CD45.1Foxp3 T cells revealed no excess activation of 
the CTLA-4/ non–T reg cells. Purified populations were 
<0.5% CD45.1+, 96–99% CD25+, and 86–92% Foxp3+.
CD4+CD25 and CD4+CD25+CTLA-4/ T cells both 
showed enhanced proliferation in thymidine incorporation 
assays compared with WT controls (Fig. 3 a). The fold increase 
was greater than that seen with CTLA-4 blockade (Fig. 2 a), 
which is consistent with a greater impact of CTLA-4 ablation 
compared with antibody-mediated blockade. Despite higher 
baseline proliferation, WT T reg cells suppressed proliferation 
of CTLA-4/ CD4+CD25 T cells to the same level as seen 
with WT CD4+CD25 T cells at ratios of 1:1 (Fig. 3 b). In 
contrast, CTLA-4/ T reg cells were severely impaired in 
their ability to suppress WT CD4+CD25 T cells (Fig. 3 c). 
In this case, the difference was unlikely to be explained solely 
by an excess of proliferation in the CTLA-4/ T reg cell 
compartment, as the differences in absolute counts (cpm) in 
the proliferation assays were well in excess of those demon-
strated for the purified CTLA-4/ CD4+CD25+ T cells 
Figure 3.  CTLA-4/ T reg cell display diminished regulatory activity during in vitro suppressor assays. Suppressor assays were performed using 
mixtures of WT and CTLA-4/ cells. (a) Proliferation of WT and CTLA-4/ CD4+CD25 and CD4+CD25+ T cells in response to T cell–depleted splenocytes 
and anti-CD3, demonstrating cell autonomous inhibitory function of CTLA-4 in the proliferation of Teff and T reg cells. (b) Suppression of 50,000 WT or 
CTLA-4/ CD4+CD25 Teff cells by increasing numbers of WT CD4+CD25+ T reg cells. (c) Suppression of 50,000 WT CD4+CD25 Teff cells by increasing 
numbers of WT or CTLA-4/ CD4+CD25+ T reg cells. (d) Suppression of 50,000 CTLA-4/ CD4+CD25 T cells by WT or CTLA-4/ CD4+CD25+ T reg cells. 
Data in a–d represent three independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.JEM VOL. 206, August 3, 2009  1723
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requirement for blockade on the effector compartment for 
the initiation of antitumor activity by anti–CTLA-4 in a thera-
peutic setting and also confirm the importance of CTLA-4 
for optimal T reg cell function. Furthermore, they demon-
strate the apparent synergy of the effects of blockade on ef-
fector and regulatory cells, revealing that only concomitant 
blockade of both compartments culminates in maximal anti-
tumor activity. This duality of immunostimulatory function 
is perhaps unique among currently available clinical thera-
peutics, although TNF receptor agonists may also influence 
the function of both compartments (Piconese et al., 2008). 
Finally,  they  demonstrate  that  although  the  expression  of 
CTLA-4 may be critical for suppressive function, outcomes 
after antibody-mediated blockade may be more subtle. This 
has great significance for the development of combinatorial 
immunotherapies and helps to explain the enhancement of 
blockade of both compartments, T reg cells only, Teff only, or 
neither compartment (i.e., WT:WT, HuTg:WT, WT:HuTg, 
and HuTg:HuTg). We aimed for the T reg cell compartment 
to be 3–5% of the total cells or up to 10% of the CD4+ popu-
lation, hence mirroring physiological levels (Fig. S5 a). After 
adoptive transfer of 1.8–2.0 × 107 total T cells, mice were left 
for 10 wk to allow equilibration. At this point, the mice were 
bled to assess equivalence before tumor challenge (Fig. S5 b). 
In all cases, the relative proportion of CD4+CD25highFoxp3+ 
was higher than in the infused mixture, and with a significantly 
higher number in those reconstituted with HuTg T reg cells. This 
finding mirrored those presented in Fig. 1 (c and d). T cell 
populations were stable between 6 and 10 wk after infusion (un-
published data). CD4+CD25highFoxp3+ cells in the reconstituted 
mice could derive from several sources, including expansion of 
the transferred CD4+CD25+ T cells or from the CD4+CD25 
T cells through either peripheral conversion of FoxP3 cells 
or up-regulation of CD25 on CD4+CD25FoxP3+ T cells. 
To confirm that the majority derived from the CD4+CD25+ 
T cell inoculum, we used a congenic marker to trace the trans-
ferred populations (Fig. S5 c). At 6 and 10 wk after transfer, 
the majority of the FoxP3+ T reg cell compartment in blood, 
LNs, and spleen was derived from the CD25+ inoculum. A 
median of 88.4% (range 80.2–92.0%) of circulating T reg cells 
were derived from this population, and similar numbers were 
derived from the CD25+ inoculum in both LNs and spleens 
(median 88.6 and 92.3%, respectively).
After B16/BL6 tumor challenge, all mice received com-
bination therapy with aMuCTLA-4 (clone 9H10, 100 µg every 
3 d from day 3) and an irradiated GM-CSF–secreting B16/BL6 
cellular vaccine (Gvax, 106 cells on days 3, 6, and 9; Fig. 4 a) 
as previously described (Quezada et al., 2006). Tumor growth 
in mice in which CTLA-4 blockade affected only the T reg 
cell compartment did not differ significantly from those in 
which it targeted neither population (Fig. 4 b). This is con-
sistent with our previous experience of therapeutic T reg cell 
depletion with either anti-CD25 mAbs or in Foxp3-DTR 
transgenic mice (Quezada et al., 2008) and with the minimal 
impact that CTLA-4 blockade had on T reg cell function in 
the in vitro experiments (Fig. 2). Unicompartmental block-
ade of the Teff cells resulted in a significant delay in tumor 
growth and improved rejection rates and long-term tumor-
free survival (Fig. 4, b and c). Combined survival from three 
experiments was 12/30 (40%; P = 0.001 compared with uni-
compartmental blockade of T reg cells). Blockade in this in-
stance would also have included that of induced T reg cells, 
but the additional blockade of the entire T reg cell compart-
ment markedly enhanced antitumor activity. Thus, bicom-
partmental blockade resulted in synergy of antitumor activity, 
with tumor rejection in the majority of mice and much de-
layed growth in the others (Fig. 4, b and c). 22/30 (73%) mice 
were long-term survivors (P = 0.0017 compared with uni-
compartmental blockade of Teff).
These data are significant for several reasons, highlighting 
the differences between genetic ablation of a molecule and 
antibody-mediated blockade. They demonstrate the absolute 
Figure 4.  CTLA-4 blockade of effector and regulatory compart-
ments synergizes to produce maximal antitumor activity. (a) Experi-
mental design. RAG2-deficient mice were reconstituted with four 
combinations of WT and HuTg T reg and non–T reg (CD4+ and CD8+) cells. 
10 wk later, they were challenged with 20 × 103 B16/BL6 melanoma cells 
intradermally. From day 3, they received combination immunotherapy 
with Gvax and aMuCTLA-4. (b) Tumor growth curves for mice reconsti-
tuted with WT Teff and T reg cells (red), HuTg Teff and WT T reg cells (green), 
WT Teff and HuTg T reg cells (black), and HuTg Teff and T reg cells (blue; n = 
10 per group). Error bars indicate SEM. Data represent three independent 
experiments. (c) Survival curves with color coding as in b. Mice were eu-
thanized when tumor volume exceeded 350 mm3. Pooled results from 
three independent experiments are shown.1724 ANTI–CTLA-4 TARGETS EFFECTOR AND REGULATORY T CELLS | Peggs et al.
Gvax and aMuCTLA-4 (as detailed in Fig. 4 a). 106 irradiated (15O Gy) Gvax 
cells were injected intradermally (100 µl) in the contralateral flank on days 3, 
6, and 9, while at the same time points, 100 µg of aMuCTLA-4 was injected 
i.p. in 200 µl PBS. Mice were monitored every 2–3 d for tumor growth.
Statistical analyses. Data were analyzed using Prism 4.0 (GraphPad Soft-
ware, Inc.). Experiments were repeated two to three times as indicated. Statis-
tical significance was determined by a Student’s t test (between two groups or 
conditions) or analysis of variance with a post-hoc test (three or more groups 
or conditions). Data for tumor survival were analyzed according to the Ka-
plan-Meier method. The log-rank test was used to compare survival curves for 
different subgroups on univariate analyses. P-values <0.05 were considered 
statistically significant.
Online supplemental material. Fig. S1 shows the scaled map of the 17-kb 
genomic DNA used for the generation of HuTg mice. Fig. S2 shows the 
regulation of cell surface and intracellular CTLA-4 expression in WT and 
HuTg mice in response to stimulation with anti-CD3. Fig. S3 shows in vitro 
suppressor assays using aHuCTLA-4 rather than aMuCTLA-4. Fig. S4 illus-
trates the approach used for isolation of CTLA-4/ T reg cells from mixed 
bone marrow chimeras. Fig. S5 illustrates the reconstitution of RAG2/ 
mice and subsequent assessment of peripheral blood, LN, and splenic pheno-
typing before tumor challenge. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20082492/DC1.
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